| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA681: Baricitinib for treating moderate to severe atopic dermatitis |
|
Medicine details |
|
| Medicine name | baricitinib (Olumiant®) |
| Formulation | 2 mg, 4mg film-coated tablets |
| Reference number | 4132 |
| Indication | Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/10/2020 |
| NICE guidance | TA681: Baricitinib for treating moderate to severe atopic dermatitis |